Crossmark Global Holdings Inc. lifted its holdings in The Allstate Co. (NYSE:ALL - Free Report) by 55.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,596 shares of the insurance provider's stock after acquiring an additional 8,046 shares during the period. Crossmark Global Holdings Inc.'s holdings in Allstate were worth $4,356,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp boosted its holdings in shares of Allstate by 1.1% in the 3rd quarter. State Street Corp now owns 11,496,306 shares of the insurance provider's stock worth $2,190,758,000 after purchasing an additional 126,922 shares during the period. Geode Capital Management LLC boosted its stake in Allstate by 1.2% during the third quarter. Geode Capital Management LLC now owns 6,228,581 shares of the insurance provider's stock worth $1,178,164,000 after buying an additional 74,537 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in Allstate by 18.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 3,000,866 shares of the insurance provider's stock worth $569,114,000 after buying an additional 472,040 shares during the period. Raymond James & Associates raised its stake in shares of Allstate by 10.6% in the third quarter. Raymond James & Associates now owns 1,517,800 shares of the insurance provider's stock valued at $287,851,000 after acquiring an additional 145,986 shares during the period. Finally, Pathway Financial Advisers LLC raised its stake in shares of Allstate by 18,472.5% in the third quarter. Pathway Financial Advisers LLC now owns 1,052,687 shares of the insurance provider's stock valued at $199,642,000 after acquiring an additional 1,047,019 shares during the period. Hedge funds and other institutional investors own 76.47% of the company's stock.
Shares of NYSE ALL opened at $185.05 on Thursday. The stock has a market capitalization of $49.00 billion, a PE ratio of 11.98, a price-to-earnings-growth ratio of 1.42 and a beta of 0.52. The company has a current ratio of 0.40, a quick ratio of 0.40 and a debt-to-equity ratio of 0.43. The Allstate Co. has a 12-month low of $153.42 and a 12-month high of $209.88. The stock's fifty day simple moving average is $195.39 and its two-hundred day simple moving average is $187.12.
Allstate (NYSE:ALL - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $3.91 earnings per share for the quarter, beating analysts' consensus estimates of $2.20 by $1.71. The company had revenue of $16.63 billion for the quarter, compared to the consensus estimate of $14.57 billion. Allstate had a return on equity of 26.67% and a net margin of 6.77%. The firm's revenue for the quarter was up 14.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.81 earnings per share. As a group, analysts expect that The Allstate Co. will post 16.72 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Thursday, January 2nd. Shareholders of record on Friday, November 29th were paid a $0.92 dividend. The ex-dividend date was Friday, November 29th. This represents a $3.68 annualized dividend and a yield of 1.99%. Allstate's dividend payout ratio (DPR) is 23.83%.
Several equities analysts recently commented on ALL shares. UBS Group upped their price target on shares of Allstate from $216.00 to $225.00 and gave the company a "buy" rating in a report on Monday, November 4th. Barclays reduced their price target on Allstate from $187.00 to $183.00 and set an "underweight" rating on the stock in a report on Monday, January 6th. The Goldman Sachs Group boosted their price objective on Allstate from $209.00 to $230.00 and gave the company a "buy" rating in a report on Friday, November 15th. Piper Sandler increased their target price on Allstate from $206.00 to $244.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 26th. Finally, Keefe, Bruyette & Woods boosted their target price on shares of Allstate from $235.00 to $243.00 and gave the company an "outperform" rating in a research note on Friday, January 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Allstate has a consensus rating of "Moderate Buy" and a consensus price target of $218.13.
Read Our Latest Research Report on Allstate
The Allstate Corporation, together with its subsidiaries, provides property and casualty, and other insurance products in the United States and Canada. It operates in five segments: Allstate Protection; Protection Services; Allstate Health and Benefits; Run-off Property-Liability; and Corporate and Other segments.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Allstate, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allstate wasn't on the list.
While Allstate currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.